Literature DB >> 7082832

Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside.

H J Weinstein, T W Griffin, J Feeney, H J Cohen, R D Propper, S E Sallan.   

Abstract

The pharmacokinetics of continuous subcutaneous cytosine arabinoside (ara-C) infusions were compared with continuous intravenous infusions. Steady-state serum ara-C levels and myelosuppression were similar with both routes of administration. CSF/serum ara-C ratios ranged from 0.14 to 0.91 (mean, 0.58). Continuous subcutaneous ara-C infusions were a convenient and reliable alternative to intravenous infusions.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7082832

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype.

Authors:  Blake S Moses; William L Slone; Patrick Thomas; Rebecca Evans; Debbie Piktel; Peggi M Angel; Callee M Walsh; Pamela S Cantrell; Stephanie L Rellick; Karen H Martin; James W Simpkins; Laura F Gibson
Journal:  Exp Hematol       Date:  2015-09-25       Impact factor: 3.084

3.  Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.

Authors:  Tiffany M Scharadin; Michael A Malfatti; Kurt Haack; Kenneth W Turteltaub; Chong-Xian Pan; Paul T Henderson; Brian A Jonas
Journal:  Chem Res Toxicol       Date:  2018-09-10       Impact factor: 3.739

Review 4.  Subcutaneous hydration by hypodermoclysis. A practical and low cost treatment for elderly patients.

Authors:  A Frisoli Junior; A P de Paula; D Feldman; F Nasri
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

5.  Use of the circuit simulation program SPICE2 for analysis of the metabolism of anticancer drugs.

Authors:  J C White
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

Review 6.  Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Authors:  Lindsay A M Rein; David A Rizzieri
Journal:  Ther Adv Hematol       Date:  2014-12

7.  Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.

Authors:  D L de Valeriola; D D Ross; A Forrest; D P Cuddy; M J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells.

Authors:  J C White; J P Rathmell; R L Capizzi
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

9.  Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.

Authors:  Jessica Dittmann; Tinka Haydn; Patrick Metzger; George A Ward; Melanie Boerries; Meike Vogler; Simone Fulda
Journal:  Cell Death Differ       Date:  2019-12-12       Impact factor: 15.828

10.  Central nervous system pharmacokinetics of high-dose cytosine arabinoside.

Authors:  J A Lopez; E Nassif; P Vannicola; J G Krikorian; R P Agarwal
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.